Consensus KalVista Pharmaceuticals, Inc. Xetra

Stocks

4XC1

US4834971032

Biotechnology & Medical Research

End-of-day quote Xetra Other stock markets 10/06/2026			5-day change	1st Jan Change
23.37 ^EUR	+0.04%		0.00%	-

08:26am	KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from S&P Biotechnology Select Industry Index	CI
08:26am	KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from S&P Global BMI Index	CI

Evolution of the Average Target: KalVista Pharmaceuticals, Inc.

Evolution of the Target Price: KalVista Pharmaceuticals, Inc.

Changes in Analyst Recommendations: KalVista Pharmaceuticals, Inc.

910c6147dbe8b34cf42a9ce3.lyDpAAMdK2Nv2Qgs1oX-KTJI4tu9YDTrk2oZT5pKdBo.zWKZMWROE1AcqGNivPOaG1EcmL7qWES75ClLH_whLG6laZ5KMmhaNQKSaw~ef6fea4e187309403343a96f7adffd3b

Analysts' recommendations: KalVista Pharmaceuticals, Inc.

05-08	Stifel Downgrades KalVista Pharmaceuticals to Hold From Buy, Adjusts Price Target to $27 From $42	MT
05-01	HC Wainwright Downgrades KalVista Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $27 From $37	MT
04-30	Leerink Downgrades KalVista Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $27 From $22	MT
22/10/25	BofA Securities Adjusts KalVista Pharmaceuticals Price Target to $29 From $36, Maintains Buy Rating	MT
02/10/25	KalVista Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
11/09/25	Drug developer KalVista Pharmaceuticals posts Q1 revenue after new product launch	RE
08/07/25	Jefferies Raises KalVista Pharmaceuticals' Price Target to $40 From $32, Buy Rating Maintained	MT
31/01/25	JMP Securities Initiates KalVista Pharmaceuticals at Market Outperform With $19 Price Target	MT
07/01/25	TD Cowen Initiates KalVista Pharmaceuticals at Buy With $30 Price Target	MT
18/12/24	BofA Securities Initiates KalVista Pharmaceuticals at Buy With $22 Price Target	MT
12/07/24	Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating	MT
14/02/24	HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating	MT
03/02/23	SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $20 From $30, Maintains Outperform Rating	MT
06/10/22	HC Wainwright Adjusts KalVista Pharmaceuticals' Price Target to $16 From $48, Reiterates Buy Rating	MT
05/10/22	SVB Securities Adjusts Price Target on KalVista Pharmaceuticals to $30 From $45, Keeps Outperform Rating	MT
05/10/22	Needham Lowers KalVista Pharmaceuticals Price Target to $24 From $38, Maintains Buy Rating	MT
08/07/22	SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $45 from $51, Keeps Outperform Rating	MT
08/07/22	Needham Adjusts Price Target on KalVista Pharmaceuticals to $38 From $42, Reiterates Buy Rating	MT
08/06/22	Stifel Nicolaus Adjusts KalVista Pharmaceuticals' Price Target to $32 From $54, Maintains Buy Rating	MT
11/03/22	Needham Adjusts KalVista Pharmaceuticals' Price Target to $42 from $48, Keeps Buy Rating	MT
11/03/22	Cantor Fitzgerald Lowers Price Target for KalVista Pharmaceuticals to $33 From $49, Maintains Overweight Rating	MT
11/12/21	Needham Adjusts KalVista Pharmaceuticals' Price Target to $48 from $50, Keeps Buy Rating	MT
19/02/21	KALVISTA PHARMACEUTICALS : Roth Capital Adjusts Price Target on KalVista Pharmaceuticals to $55 From $30, Maintains Buy Rating	MT
10/02/21	KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts Price Target on KalVista Pharmaceuticals to $51 From $39, Keeps Outperform Rating	MT
10/02/21	KALVISTA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $48 From $30, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARGENX SE					+10.97%
	WUXI APPTEC CO., LTD.					+50.41%
	BIONTECH SE					+43.68%
	INSMED INCORPORATED					+115.6%
	WUXI BIOLOGICS (CAYMAN) INC.					+57.97%
	GENMAB A/S					+43.85%
	EXELIXIS, INC.					-6.81%
	PHARMAESSENTIA CORPORATION					-17.8%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+36.43%
	Average					+37.14%
	Weighted average by Cap.					+37.37%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

27.00USD

Average target price

28.60USD

Spread / Average Target

+5.93%

High Price Target

35.00USD

Spread / Highest target

+29.63%

Low Price Target

27.00USD

Spread / Lowest Target

0.00%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Stifel Nicolaus
HC Wainwright
Leerink Partners
BofA Securities
Jefferies & Co.
JMP Securities
TD Cowen
SVB Securities LLC
Needham & Co.
Cantor Fitzgerald
Roth Capital Partners
SVB Leerink